Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $2.04M |
| Operating income | -$64.6M | -$81.2M | -$84.6M | -$100M | -$114M | -$108M |
| Operating margin | — | — | — | — | — | -5306.0% |
| Net income | -$66.5M | -$26.5M | -$12.0M | -$111M | -$149M | -$40.8M |
| Net margin | — | — | — | — | — | -2003.6% |
| EPS (diluted) | -$11.54 | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$55.6M | -$81.2M | -$71.1M | -$73.3M | -$98.1M | -$105M |
| Capital expenditures | $318K | $220K | $1.05M | $2.28M | $1.57M | $884K |
| Free cash flow | -$55.9M | -$81.4M | -$72.2M | -$75.6M | -$99.7M | -$106M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.9M | $218M | $150M | $80.4M | $44.9M | $50.5M |
| Total assets | $107M | $287M | $204M | $128M | $138M | $116M |
| Total liabilities | $36.0M | $164M | $87.4M | $115M | $191M | $113M |
| Long-term debt | — | $30.0M | — | — | $0.00 | $35.4M |
| Shareholders' equity | -$350M | $122M | $117M | $13.5M | -$52.7M | $3.11M |
| Retained earnings | -$388M | -$415M | -$427M | -$537M | -$686M | -$727M |
| Shares (wtd avg diluted) | 5.77M | 40.0M | 103M | 103M | 118M | 158M |
Every figure is extracted from Humacyte, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.